MedTrace Logo

Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents

NCT00907062 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-07-08

No results posted yet for this study

Summary

Vitiligo is a common hypopigmentation disorder with significant psychological impact if occurring before adulthood. One study investigating the use of Ginkgo biloba for the treatment of vitiligo in adults reports effectiveness, but has significant flaws. We endeavor to conduct an open label pilot clinical trial replicating the previous trial on 12 adolescents 12 to 18 years old. The purpose of the pilot is to test the feasibility of recruitment and patient retention, variability of outcome measures, and identify major safety concerns. The pilot will use 60 mg of standardized G. biloba two times per day (BID) for 12 weeks. The primary outcome will be the validated Vitiligo European Task Force (VETF) evaluation form, secondary outcomes will include the Vitiligo Area Scoring Index (VASI), assess repigmentation via photographs, and will monitor and report adverse reactions.

Conditions

  • Vitiligo Vulgaris

Interventions

DIETARY_SUPPLEMENT

Ginkgo biloba

60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill

Sponsors & Collaborators

  • Canadian Interdisciplinary Network Complementary & Alternative Medicine Research

    collaborator OTHER

  • University of Toronto

    lead OTHER

Principal Investigators

  • Orest Szczurko, ND MSc(cand) · University of Toronto, Leslie Dan Faculty of Pharmacy

  • Heather Boon, PhD · University of Toronto, Leslie Dan Faculty of Pharmacy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-10-31
Completion
2009-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00907062 on ClinicalTrials.gov